米格列奈钙

DMSO：5 mg / mL（14.95 mM;需要超声波）

体内：1。逐个添加每种溶剂：10％DMSO 90％玉米油溶解度：≥0.5mg / mL（1.50 mM）;澄清溶液2.逐个添加每种溶剂：10％DMSO 40％PEG300 5％吐温-80 45％盐水溶解度：≥0.5mg/ mL（1.50mM）;澄清溶液3.逐个加入各溶剂：10％DMSO 90％（20％SBE-β-CD在盐水中）溶解度：≥0.5mg/ mL（1.50mM）;明确解决方案

[1]. Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, et al. Effect Of Kad-1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats. Clinical and Experimental Pharmacology and Physiology. 2002, 29 (5-6): 423-427

[2]. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.European Journal of Pharmacology.2001, 431(1):119

[3]. Kiyoshi Ichikawa, Kazuyasu Maruyama, Makoto Murakami, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. European Journal of Pharmacology.2001, 3(23): 331-338

[4]. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal of Phar

[5]. Hideo Mogamia, Hiroshi Shibataa, Romi Nobusawaa, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell.. European Journal of Pharmacology: Molecular Pharmacology. 1994, 269(3): 293-29

Diabetes Obes. Metab. 14(2) , 187-9, (2012)

This study was performed to examine the efficacy and safety of mitiglinide in type 2 diabetes patients (T2DM). Enrolled patients had received treatment with diet and exercise in the previous 3 months …

Eur. J. Drug Metab. Pharmacokinet. 37(1) , 9-15, (2012)

Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate on…

Diabetes Obes. Metab. 14(2) , 130-8, (2012)

Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic β-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vas…